Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
Orforglipron: Side Effects & Safety
Known side effects, safety considerations, and adverse reaction data for Orforglipron.
Back to Orforglipron overviewData source: Side effect data comes from clinical trials, preclinical research, and anecdotal reports. No FDA-approved labeling exists for this compound.
Reported Side Effects (8 items)
| # | Side Effect |
|---|---|
| 1 | Nausea (35-42%) — higher than oral semaglutide but similar to injectable GLP-1s |
| 2 | Diarrhea (18-24%) |
| 3 | Vomiting (12-18%) |
| 4 | Constipation (14-18%) |
| 5 | Abdominal pain (8-12%) |
| 6 | Pancreatitis (0.4%) |
| 7 | Gallbladder events (0.8%) |
| 8 | Hypoglycemia (3-5%, primarily with co-administered insulin or sulfonylureas) |
Known Drug Interactions
Important: Only documented and contraindicated interactions are shown here. View all interactions including theoretical →
| Drug | Classification | Mechanism |
|---|---|---|
| proton pump inhibitors (omeprazole) | Documented | Elevated gastric pH reduces orforglipron Cmax by ~20% — separate dosing by 4 hours |
| antacids (calcium carbonate) | Documented | Chelation significantly reduces absorption — separate by 4 hours |
| hormonal contraceptives | Documented | Delayed gastric emptying may reduce contraceptive efficacy — take contraceptive 30 min before or 4+ hours after orforglipron |
| insulin and sulfonylureas | Documented | Additive glucose-lowering increases hypoglycemia risk — reduce sulfonylurea dose; reduce insulin by 20-30% |
| other GLP-1 receptor agonists | Documented | Duplicative therapy with no added benefit — do not combine |